Tocilizumab and rituximab for anti-MDA-5 positive amyopathic dermatomyositis complicated with macrophage activation syndrome and progressive fibrosing interstitial lung disease (Unbekannt)
- Neue Suche nach: Su, C-F
- Neue Suche nach: Liao, H-T
- Neue Suche nach: Tsai, C-Y
- Neue Suche nach: Su, C-F
- Neue Suche nach: Liao, H-T
- Neue Suche nach: Tsai, C-Y
In:
Scandinavian Journal of Rheumatology
;
51
, 2
;
166-168
;
2022
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Tocilizumab and rituximab for anti-MDA-5 positive amyopathic dermatomyositis complicated with macrophage activation syndrome and progressive fibrosing interstitial lung disease
-
Beteiligte:
-
Erschienen in:Scandinavian Journal of Rheumatology ; 51, 2 ; 166-168
-
Verlag:
- Neue Suche nach: Taylor & Francis
-
Erscheinungsdatum:04.03.2022
-
Format / Umfang:3 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Unbekannt
-
Datenquelle:
Inhaltsverzeichnis – Band 51, Ausgabe 2
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 87
-
Early radiological progression remains associated with long-term joint damage in real-world rheumatoid arthritis patients treated to the target of remissionVersteeg, GA / Steunebrink, LMM / Vonkeman, HE / Ten Klooster, PM / Van Der Bijl, AE / Van De Laar, MAFJ et al. | 2022
- 97
-
Smoking associated with reduced odds of Sjögren’s syndrome among rheumatoid arthritis patientsMcCoy, SS / Greenlee, RT / VanWormer, JJ / Schletzbaum, M / Bartels, CM et al. | 2022
- 102
-
Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritisMartínez-Feito, A / Navarro-Compán, V / Hernández-Breijo, B / Olariaga-Mérida, E / Peiteado, D / Villalba, A / Nuño, L / Monjo, I / Diego, C / Pascual-Salcedo, D et al. | 2022
- 110
-
Validity and reliability of the Swedish version of the Self-Efficacy for Managing Chronic Disease scale for individuals with systemic sclerosisMattsson, M / Sandqvist, G / Hesselstrand, R / Olsson, D / Kwakkenbos, L / Nordin, A / Boström, C et al. | 2022
- 120
-
Increased risk of end-stage renal disease in patients with systemic sclerosisLin, C-Y / Su, Y-J / Cheng, T-T / Wu, C-H / Chen, J-F / Yu, S-F / Chen, Y-C / Hsu, C-Y et al. | 2022
- 128
-
Sonographic findings of immunoglobulin G4-related sialadenitis and differences from Sjögren’s syndromeLiu, Y / Wang, Z / Ren, L / Zeng, Q / Bian, W / Zhang, Y / Fu, J / Chen, D / Yu, G / Zhang, S et al. | 2022
- 135
-
Comparison of outcomes using the rituximab originator MabThera with the biosimilar Truxima in patients with ANCA-associated vasculitisAntonelou, M / Abro, A / Heath, R / Iacovou, A / Ashley, C / Caplan, J / Morgan, MD / Logan, S / Harper, L / Salama, AD et al. | 2022
- 142
-
A study on echocardiographic findings in hospitalized patients with connective tissue diseasesWeiß, K / Schmidt, WA / Krause, A / Schäfer, VS et al. | 2022
- 152
-
Orbital apex syndrome on initial presentation of giant cell arteritis: a case report and review of the literatureTsuzuki, S / Tsuchiya, H / Shoda, H / Fujio, K et al. | 2022
- 154
-
Large-vessel giant cell arteritis after COVID-19 vaccineMejren, A / Sørensen, CM / Gormsen, LC / Tougaard, RS / Nielsen, BD et al. | 2022
- 156
-
Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosisCampochiaro, C / De Luca, G / Farina, N / Vignale, D / Palmisano, A / Matucci-Cerinic, M / Dagna, L et al. | 2022
- 159
-
Associations with digital pitting in patients with systemic sclerosis: results of a retrospective analysisVivekanantham, A / Dinsdale, G / Heal, C / Manning, J / Herrick, AL et al. | 2022
- 161
-
A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunitySaleh, M / Hallbeck, M / Sjöwall, C et al. | 2022
- 164
-
Pulmonary nocardiosis in a patient affected by anti-MDA5-positive amyopathic dermatomyositis under immunosuppressive therapyBiglia, A / Bozzalla Cassione, E / Zanframundo, G / Cavagna, L / Morandi, V / Bobbio Pallavicini, F / Valentini, A / Cavenaghi, G / Montecucco, C et al. | 2022
- 166
-
Tocilizumab and rituximab for anti-MDA-5 positive amyopathic dermatomyositis complicated with macrophage activation syndrome and progressive fibrosing interstitial lung diseaseSu, C-F / Liao, H-T / Tsai, C-Y et al. | 2022
- 169
-
Advisory Board of the Scandinavian Journal of Rheumatology| 2022
- 170
-
Reviewer acknowledgement November 2020 – December 2021| 2022